TENNOR THERAP-B (06872.HK): Termination Deadline for Rifasutenizol Collaboration Extended to 31 July 2027
NewTimeSpace News: On 13 November 2026, TENNOR THERAP-B (06872.HK) said in a voluntary announcement that it entered into a supplementary agreement on 12 November 2026 with Grand Life Sciences, extending from 31 December 2026 to 31 July 2027 the deadline after which Grand Life Sciences may terminate the collaboration unilaterally if the Company fails to obtain China approval for the first indication of rifasutenizol (TNP-2198).
Apart from the adjustment to the long-stop date, the other terms of the collaboration agreement remain unchanged and continue in effect. The Company signed an exclusive commercialisation agreement with Grand Life Sciences in November 2024 for rifasutenizol in Greater China excluding Taiwan, and amended it in January 2026; under the agreement, Grand Life Sciences holds exclusive rights to market, promote and distribute the product in the licensed territory and scope.
Rifasutenizol is the first new molecular entity candidate developed against Helicobacter pylori infection since the bacterium was discovered in 1982, the announcement said, adding that it works through a dual-target mechanism by inhibiting bacterial RNA polymerase to block transcription and, after activation by nitroreductase, generating free radicals that damage bacterial DNA, thereby strengthening bactericidal effect and lowering the risk of resistance. The Company has completed seven clinical trials in China, comprising two Phase I, two clinical pharmacology, two Phase II and one Phase III trial; it submitted the new drug application for rifasutenizol capsules to the NMPA in August 2025, received a request for supplementary information from the review centre in June 2026 and has submitted all requested material as of the announcement date.
The board said the supplementary agreement aligns the collaboration term and termination arrangements with the China approval and commercialisation timetable for rifasutenizol, further protecting the partnership between the parties and serving the interests of the Company and its shareholders.
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND
- KLIGHT LASER: Closes New Round Led by China Fortune-Tech Capital, Expanding Deep-Ultraviolet Output
- OSMUNDA: Closes RMB 100 Million Series D Led Exclusively by Lishui Green Valley Talent Osmunda New Fund
- INNOVENT BIO (01801.HK): Sintilimab Gets First CHMP Positive Opinion for First-Line NSCLC